NEW BREAKTHROUGH TEST DETECTS AND PREDICTS SEVERITY OF COVID-19
CHARLOTTESVILLE, Va., Sept. 15, 2022 /PRNewswire/ -- AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. The company's new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.
AMPEL's new genomic test, known as CovGENE®, has been validated by a longitudinal study in partnership with physicians in the Division of Pulmonary and Critical Care Medicine of the University of Virginia Medical Center. With careful analysis of patients admitted to the UVA Intensive Care Unit, CovGENE® demonstrated remarkable precision with a greater than 90-percent rate of accuracy. CovGENE®, can be administered by drawing a patient's blood to quickly ascertain whether a Covid-19 patient will have a mild, moderate, or severe outcome. The findings are detailed in a paper published today by Frontiers in Immunology.
"This unique collaboration with our colleagues from the University of Virginia has provided an easy and novel means to assess an individual patient's response to the SARS-CoV-2 virus and predict the clinical outcome," said Dr. Peter Lipsky, AMPEL Chief Medical Officer, CEO and co-founder. "Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with Covid-19 and reduce the number of hospitalizations, especially the most vulnerable."
AMPEL is currently working to secure a partnership with a diagnostic testing company to make CovGENE® available to the general public at a crucial time as different variants continue to emerge across the globe and with winter around the corner, when major spikes can occur. CovGENE® also holds promise in predicting long COVID, an elusive diagnosis the medical community is still trying to fully understand.
"We have come far in the prevention and treatment of COVID-19 in the past 2 years. Regardless, we still struggle to identify patients at highest risk for severe disease. Our study uses a gene analysis approach to identify an immune cell signature, distinct from other respiratory illnesses that correlates with worse outcome," said Dr. Alexandra Kadl, lead author from the University of Virginia Division of Pulmonary and Critical Care Medicine. "This knowledge will help evaluate patients' immune profile with commonly, readily available assays to identify patients at risk for bad outcome that would benefit from closer monitoring and advanced therapies to aid their recovery."
AMPEL has become a bio-industry leader in precision medicine by utilizing a data driven and machine learning approach to positively impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatments more precisely. AMPEL's co-founders Dr. Amrie Grammer and Dr. Peter Lipsky, are internationally known for their work in genomics, and were also recent panelists at the Precision Medicine World Conference.
ABOUT AMPEL BIOSOLUTIONS
AMPEL BioSolutions is a precision medicine company commercializing a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that provide clinical decision support by determining disease status, identifying molecular pathway and predicting drug options. AMPEL's technology is a cloud-based platform that hosts proprietary RNA analytic tools and machine learning algorithms covered by 20+ filed/pending patents and 80+ peer-reviewed publications in high impact journals. Disease Areas for AMPEL's precision medicine test portfolio include Systemic Lupus Erythematosus, Psoriasis, Scleroderma, Atopic Dermatitis, Lupus Nephritis, Fibromyalgia, Cardiovascular, Sjogren's Syndrome, ASD, Wellness, Lung Cancer and SARS-Cov2. AMPEL's technology covers over 95% of all known genes and AMPEL's exclusive curated database of >15,000 individual gene expression profiles with rich clinical information fuels machine learning predictions based on evidence. AMPEL BioSolutions was elected to the Coalition for 21st Century Precision Medicine in early 2022.
MEDIA CONTACT
Amrie C. Grammer PhD
Co-Founder, President and CSO
AMPEL BioSolutions
Email: [email protected]
Cell: 240-401-8889
SOURCE AMPEL BioSolutions
Share this article